Deep brain stimulation (DBS) remains a cornerstone of advanced Parkinson's disease therapy. MDS 2026 showcases significant advances in surgical techniques, targeting, device technology, and programming strategies.
- Most common target for PD in most centers
- Benefits: Significant reduction in levodopa dose (50-70%), motor symptoms
- Considerations: May worsen speech, cognition, mood
- Alternative target gaining popularity
- Benefits: Better dyskinesia control, fewer cognitive/behavioral side effects
- Considerations: Slightly less medication reduction than STN
- Experimental target for gaitFreeze and axial symptoms
- Early results show modest benefit
- Ongoing studies investigate optimal parameters
- High-resolution MRI — 7T MRI for precise anatomy
- Diffusion tensor imaging (DTI) — Visualize white matter tracts
- Intraoperative CT — Verify lead location
- MER integration — Microelectrode recording confirmation
- Lead implantation accuracy — ±0.5mm with frame-based systems
- Asleep DBS — General anesthesia with image guidance
- ** frameless systems** — Increased patient comfort
###Directional Leads
- ** segmented electrodes** — Current steering in 3D
- Benefits: Customize stimulation, reduce side effects
- Data from MDS 2026: 30% improvement in therapeutic window
- Adaptive DBS — Responsive to neural biomarkers
- Sensing capabilities — Local field potential monitoring
- VPED algorithm — Automated programming based on patient state
- Smaller profiles — Less visible
- Longer battery life — Up to 15-20 years with rechargeable
- MR conditional — Safe for MRI scanning
- Multiple programs — Different frequencies on different contacts
- Benefits: Optimize different symptoms (tremor, bradykinesia, dyskinesia)
- High-frequency (130-180 Hz) — Standard for PD
- Low-frequency (60-80 Hz) — May help gaitFreeze
- Battery-efficient settings — Reduce device replacement
- Symptom-specific programming — Based on patient presentation
- Machine learning — Optimize parameters algorithmically
- Remote programming — Telemedicine for adjustments
| Outcome |
STN DBS |
GPi DBS |
| UPDRS III (off-med) |
50-60% improvement |
40-50% improvement |
| On time |
+4-6 hours/day |
+3-5 hours/day |
| Levodopa reduction |
50-70% |
20-40% |
| Dyskinesia reduction |
70-90% |
80-90% |
- PDQ-39: 30-50% improvement
- Activities of daily living: Significant improvement
- Caregiver burden: Reduced
¶ Complications and Management
- Intracranial hemorrhage: 1-2% (often asymptomatic)
- Infection: 3-5%
- Hardware complications: 5-10%
- Speech disturbances: 10-30%
- Cognitive decline: 5-15%
- Mood changes: 5-10%
- Dysarthria: Controllable with programming
MDS 2026 highlights emerging research:
- Gene therapy combined with DBS — Synergistic effects
- Biomarker-responsive stimulation — Automation based on clinical state
- DBS for prodromal PD — Early intervention
- Network-based targeting — Personalized connectome approaches